Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Adverum Biotechnologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ADVM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ADVM's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ADVM underperformed the US Biotechs industry which returned 33.5% over the past year.
Return vs Market: ADVM underperformed the US Market which returned 38.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Adverum Biotechnologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
1 month ago | Simply Wall StTrade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
1 month ago | Simply Wall StHow Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Is Adverum Biotechnologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ADVM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ADVM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ADVM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ADVM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADVM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADVM is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (4.2x).
How is Adverum Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADVM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADVM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADVM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADVM's revenue (74.8% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: ADVM's revenue (74.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ADVM is forecast to be unprofitable in 3 years.
How has Adverum Biotechnologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADVM is currently unprofitable.
Growing Profit Margin: ADVM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADVM is unprofitable, and losses have increased over the past 5 years at a rate of 1% per year.
Accelerating Growth: Unable to compare ADVM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.9%).
Return on Equity
High ROE: ADVM has a negative Return on Equity (-21.26%), as it is currently unprofitable.
How is Adverum Biotechnologies's financial position?
Financial Position Analysis
Short Term Liabilities: ADVM's short term assets ($459.7M) exceed its short term liabilities ($16.1M).
Long Term Liabilities: ADVM's short term assets ($459.7M) exceed its long term liabilities ($26.9M).
Debt to Equity History and Analysis
Debt Level: ADVM is debt free.
Reducing Debt: ADVM had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADVM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ADVM has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.4% each year
What is Adverum Biotechnologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADVM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADVM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADVM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Laurent Fischer (56 yo)
Dr. Laurent Fischer, M.D., serves as Chief Executive Officer and Director at Adverum Biotechnologies, Inc. since June 15, 2020. He has been Senior Advisor on the Frazier Healthcare Partners' Life Sciences ...
|Chief Medical Officer||1.83yrs||US$2.38m||0.0014% |
|CEO & Director||0.67yr||no data||0.017% |
|Chief Technology Officer||1yr||no data||no data|
|Vice President of Investor Relations & Corporate Communications||1.5yrs||no data||no data|
|Chief Legal Officer & Corporate Secretary||1.33yrs||no data||0.011% |
|Vice President of Human Resources||1.5yrs||no data||no data|
|Chief Business Officer||no data||no data||no data|
Experienced Management: ADVM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|CEO & Director||0.67yr||no data||0.017% |
|Independent Director||4.75yrs||US$468.10k||0.019% |
|Independent Director||1.75yrs||US$789.81k||0.055% |
|Independent Director||0.83yr||no data||no data|
|Independent Chairman||1.75yrs||US$504.00k||0.080% |
|Director||0.17yr||no data||no data|
|Independent Director||3.42yrs||US$478.57k||0.033% |
|Independent Director||1.75yrs||US$785.74k||0% |
|Independent Director||1.75yrs||US$790.96k||0% |
|Independent Director||no data||no data||no data|
Experienced Board: ADVM's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ADVM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.6%.
Adverum Biotechnologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Adverum Biotechnologies, Inc.
- Ticker: ADVM
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.251b
- Shares outstanding: 97.48m
- Website: https://www.adverum.com
Number of Employees
- Adverum Biotechnologies, Inc.
- 800 Saginaw Drive
- Redwood City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ADVM||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Aug 2014|
|AVU||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2014|
|0HA3||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Aug 2014|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes AD...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/02/28 00:08|
|End of Day Share Price||2021/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.